ketamine
Commercial- Indications
- Depression, Anxiety, Bipolar disorder, Post-traumatic stress disorder
Company intelligence / Profile preview
Braxia operates five multidisciplinary clinics across Canada offering rapid-onset ketamine treatments with significant year-over-year growth in treatment volumes. The company claims world-leading expertise in depression research with published protocols setting standards of care. It develops proprietary formulations/delivery systems for ketamine/psychedelics but no late-stage novel drug assets reported publicly as commercialized yet.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Braxia Scientific.